What is an adaptive platform trial?
An Adaptive Platform trial uses a perpetual trial design to test a range of different treatments within a common trial setup. New treatments are added to the platform as they become available, and existing treatments are stopped once the data indicate it is or is not working. This way, results are generated much more quickly than a standard clinical trial in a cost-effective and resource-efficient manner. The trial design also allows us to investigate whether treatments work best when used alone or in combination with each other.
Why we are doing an adaptive platform trial in kidney disease?
There have been several new therapies recently that have been shown to slow the progression of kidney disease and some that are on the horizon and show promise. We anticipate that these treatments will need to be used in combination with each other to gain the maximum benefit for patients.
CAPTIVATE uses an adaptive trial design so that high quality evidence on multiple new treatments and combinations of agents can be developed in a shorter timeframe. The ‘perpetual’ analysis of study results means that effective study treatments will be found quicker, and ineffective treatments will be stopped quicker. Our end goal of CAPTIVATE is to continuously improve on the treatment options available to people living with kidney disease, until we can prevent the disease progression altogether.